Bioxcel therapeutics announces fda clearance of ind application for bxcl501 for the treatment of opioid withdrawal symptoms

Bioxcel therapeutics announces fda clearance of ind application for bxcl501 for the treatment of opioid withdrawal symptoms.

BTAI Ratings Summary

BTAI Quant Ranking